KYTHERA Biopharmaceuticals (NASDAQ:KYTH)

CAPS Rating: 1 out of 5

Results 1 - 2 of 2


Member Avatar OklaBoston (67.36) Submitted: 10/19/2013 6:55:39 PM : Underperform Start Price: $41.18 KYTH Score: +20.28

Insiders starting to sell shares on the open market, so what I call the "honeymoon" phase of the IPO cycle is probably over for this stock.

I coined that phrase in some blog posts last year.


Member Avatar zzlangerhans (99.77) Submitted: 5/12/2013 3:40:36 AM : Outperform Start Price: $23.19 KYTH Score: +30.80

My disastrous flirtation with FibroCell tells me I don't know much about the market for cosmetic therapies, but I'll hazard a green thumb on Kythera ahead of the topline data from the phase III trials of ATX-101 in chin fat. The two European phase III trials have already been reported as positive, which indicates to me that the data is likely to be good. The share price was over 30 at the beginning of the year but the stock couldn't maintain the upward momentum. Despite the lofty share price, the market cap is just a little over 400M.

I wouldn't risk real money here, and sadly Kythera is too young as a public company to have an options market established, so this will remain a virtual play.

Results 1 - 2 of 2

Featured Broker Partners